NCT07313852尚未招募1 期
A Phase 1/2 Study of Concurrent Inotuzumab and Subcutaneous Blinatumomab in Adult Patients With B-cell Acute Lymphoblastic Leukemia
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Phase I: Maximum Tolerated Dose/MTD
研究概览
简要总结
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of age.
- •Newly diagnosed CD19+ and CD22+ B-ALL with the following characteristics
- •Patients ≥55 years old, OR
- •Patients 18-54 years old who decline or are deemed unfit for conventional chemotherapy with at least one of the following criteria:
- •ECOG performance status of 2 or more
- •Severe cardiac comorbidity (including congestive heart failure requiring treatment)
- •Known pulmonary comorbidity (including DLCO ≤65% or FEV1 ≤65%)
- •Renal comorbidity (including creatinine clearance 30-45 mL/min)
- •Relapsed or refractory CD19+ and CD22+ B-ALL
- •Patients with extramedullary disease will be allowed as long as they have detectable disease by flow cytometry in the bone marrow
- •Peripheral absolute lymphoblast count of ≤ 10,000/ml after pre-phase (not required for enrollment but required to proceed with first dose of inotuzumab).
- •Philadelphia chromosome negative by FISH/karyotype for t(19;22) or RT PCR for bcr-abl transcript.
- •CD19 and CD22 expression will be confirmed by enrolling institutions prior to study registration by flow cytometry and/or IHC.
- •Creatinine clearance ≥30 mL/min
- •Total bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤3.0x upper limit of normal (ULN)
- •QTcF ≤ 480
- •Ejection fraction ≥ 50%
排除标准
- •Patients with Burkitt's lymphoma, T-ALL, CML in lymphoid blast crisis and mixed phenotype acute leukemia (MPAL).
- •Patients with newly diagnosed B-ALL who received prior treatments, with the exception of corticosteroid, hydroxyurea, or one dose of vincristine, are ineligible.
- •Patients with Ph+ B-ALL by FISH or RT PCR.
- •ECOG performance status >
- •Left ventricular ejection fraction (LVEF) <50%.
- •History of sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD).
- •Prior treatment with inotuzumab
- •History of liver cirrhosis
- •Ongoing need for systemic T-cell suppressive therapy (e.g. corticosteroids, tacrolimus, cyclosporine, etc.) Patients need to be off calcineurin inhibitors for at least 4 weeks in order to be eligible for enrollment.
- •Active Grade 2-4 acute graft versus host disease (GVHD), graded with the modified Glucksberg criteria and/or GVHD requiring systemic steroids in excess of physiologic replacement
- •Moderate or severe chronic GVHD graded with the NIH 2014 criteria
- •Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for the following time periods: female patients of reproductive potential should use effective contraception during treatment and for 8 months after last treatment dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.
- •Patients with HIV or active hepatitis B or hepatitis C infection are ineligible. Patients with a prior history of hepatitis B or hepatitis C who have negative HBV/HCV PCR respectively at the time of screening are eligible
- •Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
- •Patients with history or presence of clinically significant neurological disorders such as epilepsy, generalized seizure disorder, or severe brain injuries.
- •Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study.
研究组 & 干预措施
Phase I: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Experimental
Participants will be newly diagnosed with CD19+ and CD22+ B-cell Acute Lymphoblastic Leukemia
干预措施: Blinatumomab Injection (Drug)
Phase II: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Experimental
Participants who receive at least one dose of the Inotuzumab will be evaluable for the primary endpoint
干预措施: Blinatumomab Injection (Drug)
结局指标
主要结局
Phase I: Maximum Tolerated Dose/MTD
时间窗: up to 1 year
To establish the MTD in phase 1 part of the study
Phase II: Rate of MRD negative CR/CRi (10-4 threshold) at the end of induction.
时间窗: up to 1 year
To evaluate the efficacy of concurrent inotuzumab at the RP2D and subcutaneous blinatumomab in participants as assessed by rate of MRD negative CR/CRi (10-4 threshold) at the end of induction.
Rate of MRD negative CR/CRi at the end of induction
时间窗: up to 1 year
To evaluate the efficacy of concurrent inotuzumab and subcutaneous blinatumomab in patients older (≥55) or 18-55 years that refuse or are unfit for intensive chemotherapy with newly diagnosed B-cell Acute Lymphoblastic Leukemia as assessed by rate of MRD negative CR/CRi (10-4 threshold) at the end of induction.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNCT07283640M.D. Anderson Cancer Center20
招募中
2 期
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment2024-516061-36-00Hellenic Society Of Hematology51
招募中
2 期
Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial.Ulcerative colitis2023-506452-25-00Medical University Of Lodz172
招募中
2 期
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaMantle Cell LymphomaNCT07261163Institute of Hematology & Blood Diseases Hospital, China37
招募中
3 期
Efficacy and Safety of Obinutuzumab versus Rituximab in childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : à double-blind multicenter randomized controlled study2024-514240-93-00Assistance Publique Hopitaux De Paris88